Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.30M |
$3.00
-1.64%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.17M |
$5.62
-1.40%
|
|
INIS
International Isotopes Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$967348 |
$0.10
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$876899 |
$1.23
-0.41%
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$628469 |
$1.54
+10.36%
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
|
$551676 |
$3.81
-2.19%
|
|
RGBP
Regen BioPharma, Inc.
RGBP focuses on oncology/s Cancer immunotherapy and regenerative medicine, aligning with Biotech - Oncology.
|
$409265 |
$0.01
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$401581 |
$1.25
-0.40%
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$371319 |
$0.75
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$349274 |
$0.14
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$283088 |
$2.81
-4.58%
|
|
CERO
CERo Therapeutics Holdings, Inc.
CER-T is a cell therapy platform with lead candidate CER-1236, indicating direct cell-based therapeutic products.
|
$27220 |
$0.10
+37.02%
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$16496 |
$1.02
-0.97%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$13057 |
$0.01
|
|
SMFL
Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
|
$1366 |
$0.01
|
|
NCNA
NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
|
N/A |
$4.04
+8.76%
|
Showing page 25 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
